Table 3 Clinical outcome comparison after TKA between PD and control patients
From: The effect of Parkinson’s disease on total knee arthroplasty: a systematic review and meta-analysis
Year | Author | Preoperation (PD) | Preoperation (Control) | Postoperation (PD) | Postoperation (Control) | Others | |
|---|---|---|---|---|---|---|---|
Acta Orthop. Belg | 2013 | Craig | KSS 30.5 ROM 95 (30–120) | KSS 32.5 ROM 88 (46–125) | KSS 91 ROM 100 (70–125) | KSS 88 ROM 110 (10–125) | Pain score, ROM were comparable in both group and no functional improvement in PD at postoperative 1 year |
J Arthroplasty | 2017 | Rodon | Functional SF-12 score 27.7 ± 1.06 | Functional SF-12 score 32.9 ± 1.14 | Functional SF-12 score 37.1 ± 1.67 10 year survival: 66.2% | Functional SF-12 score 44.1 ± 1.27 | Improvement in functional scores was significantly less in patients with PD compared to controls (p = 0.003) Patients with PD who received TKA demonstrated decreased survivorship than their matched controls (p = 0.0045) |
J arthroplasty | 2018 | Wong | OKS 38.3 ± 7.2 ΔOKS 18.6 ± 6.8 ROM 113.2 ± 8.3 ΔROM 12.34 ± 5.4 | OKS 40.2 ± 6.5 (p = 0.34) ΔOKS 16.5 ± 8.1 (p = 0.45) ROM 114.4 ± 9.8 (p = 0.62) ΔROM 12.2 ± 4.5 (p = 0.96) | |||
J Orthop Surg Res | 2019 | Xiao | KSS score Pain 21.11 ± 9.63 ROM 22.22 ± 1.86 Stability 17.89 ± 2.00 Total 61.22 ± 9.66 KSFS 39.72 ± 6.52 SF-12 (PCS) 15.61 ± 3.55 SF-12 (MCS) 20.28 ± 3.49 WOMAC pain 8.39 ± 2.55 WOMAC stiffness 2.94 ± 1.30 WOMAC function 38.00 ± 6.73 ROM: 111.11 ± 9.32 | KSS score Pain 43.61 ± 12.10 (p < 0.01) ROM 23.61 ± 1.61 (p < 0.01) Stability 24.11 ± 1.18 (p < 0.01) Total 91.33 ± 12.57 (p < 0.01) KSFS 58.06 ± 31.11 (p = 0.02) SF-12 (PCS) 20.17 ± 5.08 (p < 0.01) SF-12 (MCS) 24.00 ± 5.16 (p = 0.02) WOMAC pain 3.39 ± 4.55 (p < 0.01) WOMAC stiffness 0.61 ± 1.50 (p < 0.01) WOMAC function 26.44 ± 15.24 (p < 0.01) ROM: 118.33 ± 8.22 (p < 0.01) | HY I, II stage show better result (KSS total, WOMAC, pain, function) than HY, III, IV and SF-12, WOMAC score correlated with HY stage (p < 0.01) | ||
AOTS | 2020 | Veronica | KSS 32 (20–45) KSFS 34 (28–52) VAS 8 ROM 97 | KSS 71 (50–81) KSFS 59 (25–76) VAS 5 ROM 116 | |||
J Arthroplasty | 2020 | Goh | KSKS 36.5 ± 19.3 KSFS 39.1 ± 24.9 OKS 20.5 ± 10.5 SF-36 PCS 28.8 ± 8.9 SF-36 MCS 45.5 ± 11.5 ROM 108.0 ± 17.7 | KSKS 33.1 ± 16.3 KSFS 34.8 ± 25.3 OKS 19.9 ± 9.2 SF-36 PCS 29.3 ± 10.8 SF-36 MCS 47.0 ± 11.6 ROM 105.4 ± 29.2 | KSKS 82.0 ± 16.6 KSFS 48.2 ± 26.6 OKS 34.6 ± 10.0 SF-36 PCS 39.6 ± 11.3 SF-36 MCS 50.7 ± 12.2 ROM 110.4 ± 15.1 | KSKS 81.9 ± 18.5 (p = 0.978) KSFS 67.2 ± 21.4 (p < 0.001) OKS 39.0 ± 8.7 (p = 0.014) SF-36 PCS 43.5 ± 13.4 (p = 0.092) SF-36 MCS 54.1 ± 9.9 (p = 0.109) ROM 112.5 ± 17.6 (p = 0.490) | |
J Orthop Sci | 2020 | Ergin | KSS 45.4 ± 16.8 ROM 93.9 ± 17.0 Flexion contracture 8.85 ± 7.12 | KSS 38.8 ± 11.5 ROM 100.4 ± 14.6 Flexion contracture 7.41 ± 4.84 | KSS 85.6 ± 7.60 ROM 99.5 ± 9.37 | KSS 85.6 ± 10.0 ROM 109.2 ± 10.2 | Similar outcomes compared with general population despite disease severity and progression Mean increase in KSS and ROM values were significantly higher for high-grade patients (p < 0.05) High-grade PD: similar outcome |
Int Orthop | 2021 | Baek | KSS 36.8 ± 5.4 Functional score 35.5 ± 4.4 | KSS 37.1 ± 4.8 Functional score 35.9 ± 6.7 | KSS 60.0 ± 24.5 Functional score 57.5 ± 29.7 Survival rate: 89.7% | KSS 80.7 ± 13.1 Functional score 81.5 ± 17.4 Survival rate: 98.3% | |
BMC Musculoskeletal Dis | 2022 | Y. Zong | EQ-pain and discomfort 2.19 ± 0.60 PDQ-function 57.8 ± 26.3 | EQ-pain and discomfort 2.40 ± 0.57 PDQ-function 46.7 ± 21.6 | EQ-pain and discomfort 2.37 ± 0.49 PDQ-function 53.3 ± 21.0 | EQ-pain and discomfort 1.92 ± 0.58 PDQ-function 32.8 ± 24.3 |